PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer

doi:10.3390/books978-3-0365-8157-6

dc.contributor.editor	Curtin, Nicola
dc.contributor.editor	Bay, Péter
dc.date.accessioned	2023-08-08T15:13:37Z
dc.date.available	2023-08-08T15:13:37Z
dc.date.issued	2023
dc.identifier	ONIX_20230808_9783036581569_37
dc.identifier.uri	https://directory.doabooks.org/handle/20.500.12854/112469
dc.description.abstract	This Special Issue of Cancers contains research and review articles on “PARPs, PAR and NAD metabolism and their inhibitors in Cancer”. It focuses on selected papers from the PARP2019 conference on “New Avenues in Basic and Translational PARP research”, that took place in Budapest (Hungary), on 20–23 May 2019.
dc.language	English
dc.subject.classification	thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general	en_US
dc.subject.classification	thema EDItEUR::P Mathematics and Science::PS Biology, life sciences	en_US
dc.subject.classification	thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSB Biochemistry	en_US
dc.subject.other	MDS
dc.subject.other	PARP inhibitors
dc.subject.other	olaparib
dc.subject.other	hematopoietic differentiation
dc.subject.other	PARP1
dc.subject.other	AML
dc.subject.other	poly-ADP-ribose polymerase 1 (PARP1)
dc.subject.other	brahma-related gene 1 (BRG1)
dc.subject.other	histone acetyltransferase p300 (EP300)
dc.subject.other	gene transcription
dc.subject.other	cancer cell
dc.subject.other	head and neck squamous cell carcinoma
dc.subject.other	CAL27
dc.subject.other	SCC90
dc.subject.other	p60/p150 CAF-1 subunits
dc.subject.other	DNA repair
dc.subject.other	homologous recombination
dc.subject.other	biomarkers
dc.subject.other	personalized treatment
dc.subject.other	UVB
dc.subject.other	PARP
dc.subject.other	mitochondria
dc.subject.other	metabolism
dc.subject.other	biogenesis
dc.subject.other	autophagy
dc.subject.other	carcinogenesis
dc.subject.other	transcription
dc.subject.other	PARylation
dc.subject.other	DNA damage
dc.subject.other	transcription silencing
dc.subject.other	carryover effect
dc.subject.other	TOP1 activity
dc.subject.other	TDP1
dc.subject.other	irinotecan
dc.subject.other	immunomodulation
dc.subject.other	tumor microenvironment
dc.subject.other	trapping
dc.subject.other	cancer therapeutic strategy
dc.subject.other	arginine-specific mono-ADP-ribosylation
dc.subject.other	bacterial toxin
dc.subject.other	cholera toxin
dc.subject.other	ART1
dc.subject.other	ARH1
dc.subject.other	tumorigenesis
dc.subject.other	loss of heterozygosity
dc.subject.other	membrane repair
dc.subject.other	gender bias
dc.subject.other	Syk
dc.subject.other	EGFR
dc.subject.other	squamous cell carcinoma
dc.subject.other	PARP-Akt interplay
dc.subject.other	PI3K
dc.subject.other	mTOR
dc.subject.other	cytoprotection
dc.subject.other	apoptosis resistance
dc.subject.other	oxidative stress
dc.subject.other	mitochondrial protection
dc.subject.other	drug development
dc.subject.other	synthetic lethality
dc.subject.other	clinical trials
dc.subject.other	ADP-ribosylation
dc.subject.other	cancer
dc.subject.other	macrodomain
dc.subject.other	ADP-ribosyl hydrolase
dc.subject.other	ARTD
dc.subject.other	MACROD1
dc.subject.other	MACROD2
dc.subject.other	TARG1
dc.subject.other	ATM
dc.subject.other	ATR
dc.subject.other	PARP inhibitor
dc.subject.other	prostate cancer
dc.subject.other	pancreatic cancer
dc.subject.other	lung cancer
dc.subject.other	Tumor microenvironment
dc.subject.other	PARPs
dc.subject.other	hypoxia
dc.subject.other	CHK1
dc.subject.other	replication stress
dc.subject.other	homologous recombination DNA repair
dc.subject.other	cell cycle
dc.subject.other	cytotoxicity
dc.subject.other	PARP Inhibitors
dc.subject.other	beta-lapachone
dc.subject.other	NQO1
dc.subject.other	PARG
dc.subject.other	NAMPT
dc.subject.other	cancer therapeutics
dc.subject.other	cMET
dc.subject.other	poly (ADP-ribose) glycohydrolase
dc.subject.other	radiosensitization
dc.subject.other	poly (ADP-ribose) polymerase
dc.subject.other	ES cells
dc.subject.other	poly (ADP-ribose) polymerase inhibitors (PARPi)
dc.subject.other	ataxia telangiectasia and Rad3 related inhibitors (ATRi)
dc.subject.other	cell cycle checkpoints
dc.subject.other	NAD+
dc.subject.other	NMNAT1
dc.subject.other	cisplatin
dc.subject.other	chemotherapy
dc.subject.other	apoptosis
dc.subject.other	osteosarcoma
dc.subject.other	DNA damage response
dc.subject.other	immunotherapy
dc.subject.other	immune checkpoint inhibitor
dc.subject.other	PD-1
dc.subject.other	PD-L1
dc.subject.other	CTLA-4
dc.subject.other	combination therapy
dc.subject.other	solid tumors
dc.subject.other	the PARP inhibitor PJ34
dc.subject.other	distorted mitotic spindles
dc.subject.other	exclusive eradication of human cancer cells
dc.subject.other	nucleolus
dc.subject.other	poly(ADP-ribosyl)ation
dc.subject.other	ARTDs
dc.subject.other	n/a
dc.title	PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer
dc.type	book
oapen.identifier.doi	10.3390/books978-3-0365-8157-6
oapen.relation.isPublishedBy	46cabcaa-dd94-4bfe-87b4-55023c1b36d0
oapen.relation.isbn	9783036581569
oapen.relation.isbn	9783036581576
oapen.pages	462
oapen.place.publication	Basel

Files in this item

Files	Size	Format	View
There are no files associated with this item.

This item appears in the following Collection(s)

Imported or submitted locally

Show simple item record

Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/